GlassScriptPhysician profile
Razmik Ohanjanian
NPI 1265488845
$17,197.70
in general payments reported to CMS, 2019-2025
61 companies · $1,829 in 2025
The $1,829 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,153 · 2020: $2,391 · 2021: $3,114 · 2022: $2,491 · 2023: $2,091 · 2024: $2,129 · 2025: $1,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,030 · Education: $18.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,029.84 |
| Education | $18.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,074.98 | 2019-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,764.59 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Esperion Therapeutics, INC. | $1,320.00 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,108.85 | 2019-2025 | Jardiance |
| Abbvie INC. | $862.34 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $820.92 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $758.85 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $741.97 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $719.91 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $536.90 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $492.22 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $487.15 | 2019-2024 | Xarelto |
| Ardelyx, INC. | $444.57 | 2024-2025 | Ibsrela |
| Astellas Pharma US INC | $417.52 | 2019-2022 | |
| Lilly USA, LLC | $415.05 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Razmik Ohanjanian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.